We studied morphological changes in the prostate ventral lobe, proliferative activity of the epithelium in prostate acini, and the levels of prolactin and prostate-specific antigen in the blood serum of Sprague-Dawley rats after repeated injections of sulpiride in a dose of 40 mg/ kg over 30 and 60 days and in 10 and 30 days after withdrawal. Morphological and morphometrical analysis of hyperplastic changes in the prostate ventral lobe was performed. Ki-67+ proliferating epithelial cells in the acini were counted. The dynamics of serum concentrations of prolactin and prostate-specific antigen was evaluated by ELISA. Morphological and morphometrical analysis and evaluation of the content of Ki-67+ cells demonstrated epithelium hyperplasia in the prostate ventral lobe after sulpiride treatment for 30 or 60 days and in 10 days after withdrawal, but serum level of prostate-specific antigen did not differ from the control. After 60-day sulpiride treatment and in 30 days after withdrawal, pronounced hyperplastic changes of prostate and elevated concentrations of prostate-specific antigen (but not prolactin) were observed. Thus, administration of sulpiride (40 mg/kg) to Sprague-Dawley rats for 60 days allows, by morphological criteria and serum level of prostate-specific antigen, to model stable hyperplastic changes in the prostate corresponding to benign prostatic hyperplasia in humans.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Tishevskaya NV, Maksakov DA, Golovneva ES. Morphological features of sulpiride model of benign prostatic hyperplasia in rats. Eksp. Klin. Urologiya. 2017;(2):16-19. Russian.
Tsvetkov IS, Mkhitarov VA. Immunomorphological characteristics experimental chronic autoimmune prostatitis. Ross. Med.-Biol. Vestn. 2010;18(3):10-17. Russian.
Ajayi A, Abraham K. Understanding the role of estrogen in the development of benign prostatic hyperplasia. African J. Urol. 2018;24(2):93-97.
Cakir SS, Polat EC, Ozcan L, Besiroglu H, Ötunctemur A, Ozbek E. The effect of prostatic inflammation on clinical outcomes in patients with benign prostate hyperplasia. Prostate Int. 2018;6(2):71-74.
Carson C 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61(4, Suppl. 1):2-7.
Cheon JH, Kim HS. Role of GV1001 on benign prostatic hyperplasia in Sprague-Dawley rats. Toxicol. Lett. 2015;238:S244-S228.
Dzhalilova DS, Kosyreva AM, Diatroptov ME, Makarova OV. Relationship between hypoxic resistance and the phase of 4-day corticosterone biorhythm in adult male rats. Bull. Exp. Biol. Med. 2017;163(5):687-690.
Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur. Urol. 2007;51(5):1202-1216.
Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: Past, present and future. Differentiation. 2011;82(4-5):184-199.
Pascual-Mathey LI, Rojas-Duran F, Aranda-Abreu G.E, Manzo J, Herrera-Covarrubias D, Muñoz-Zavaleta DA, Garcia LI, Hernandez ME. Effect of hyperprolactinemia on PRL-receptor expression and activation of stat and mapk cell signaling in the prostate of long-term sexually-active rats. Physiol. Behav. 2016;157:170-177.
Popovics P, Schally AV, Salgueiro L, Kovacs K, Rick FG. Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells. Proc. Natl Acad. Sci. USA. 2017;114(6):1359-1364.
Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N. Engl. J. Med. 2012;367(3):248-257.
Tritos NA, Klibanski A. Prolactin and its role in human reproduction. Yen & Jaffe’s Reproductive Endocrinology. Strauss J, Barbieri R, Gargiulo A, eds. Elsevier, 2019. P. 58-74.
Van Coppenolle F, Slomianny C, Carpentier F, Le Bourhis X, Ahidouch A, Croix D, Legrand G, Dewailly E, Fournier S, Cousse H, Authie D, Raynaud JP, Beauvillain JC, Dupouy JP, Prevarskaya N. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am. J Physiol Endocrinol. Metab. 2017;280(1):E120-E129.
Yousuf S, Duan M, Moen EL, Cross-Knorr S, Brilliant K, Bonavida B, LaValle T, Yeung KC, Al-Mulla F, Chin E, Chatterjee D. Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer. PLoS One. 2014;9(3. ID e92478. doi: 10.1371/journal.pone.0092478
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 168, No. 10, pp. 523-528, October, 2019
Rights and permissions
About this article
Cite this article
Tsvetkov, I.S., Kosyreva, A.M., Mkhitarov, V.A. et al. Morphological and Biochemical Characteristics of Prostate Hyperplasia during Sulpiride Treatment. Bull Exp Biol Med 168, 533–537 (2020). https://doi.org/10.1007/s10517-020-04748-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-020-04748-2